Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.

Small-Molecule Trk Agonists: Where Do We Go from Here?

Open access
Thompson, Tye S., Sefiani, Arthur, Burgess, Kevin · 2025 · Journal of Medicinal Chemistry

Abstract

About two decades ago, there were no validated, agonistic small-molecule modulators of Trk (tropomyosin receptor kinase). High-throughput screening of commercial libraries seemed an attractive way to identify starting structures when the research community became aware of their potential for treatment of neurodegeneration and traumatic injuries (e.g., stroke) because this strategy avoids high-level chemical expertise for molecular design and synthesis. Cost and effort constraints arising from library acquisition and assays imposed limitations on numbers of compounds tested, so filtering to reduce library sizes before screening was routine. One of the criteria was to prioritize existing pharmaceuticals because these had known toxicity profiles and side effects, at least in some delivery and dosing regimens, and many cases had proven blood brain barrier (BBB) permeabilities. This review gives our perspective on how these efforts transpired, lessons learned, and constraints which hold back development in this area at the present time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.4c02365

Cites

166 of 166 references verified0 citation errors · 0 not checkable

Statistics

Figures

1 (a) Neurotrophins are dimeric (gray) and interact selectively with their primary targets (black arrows) but also show cross-reactivity with other Trks (broad dashed line). All the Neurotrophins interact with p75 (thin dashed line). (b) Some mechanisms by which monomeric small molecules might activate Trk receptors.
1 (a) Neurotrophins are dimeric (gray) and interact selectively with their primary targets (black arrows) but also show cross-reactivity with other Trks (broad dashed line). All the Neurotrophins interact with p75 (thin dashed line). (b) Some mechanisms by which monomeric small molecules might activate Trk receptors.CC BY · PubMed Central
2 (a) NGF interaction with the extracellular domain of TrkA (PDB 2IFG). (b) NGF interacting with the extracellular domain of p75 (PDB 1SG1).
2 (a) NGF interaction with the extracellular domain of TrkA (PDB 2IFG). (b) NGF interacting with the extracellular domain of p75 (PDB 1SG1).CC BY · PubMed Central
3 Most widely studied small molecule leads for Trk agonism. Reported Trk selectivities in blue, outline of observations in green, and potential issues in red.
3 Most widely studied small molecule leads for Trk agonism. Reported Trk selectivities in blue, outline of observations in green, and potential issues in red.CC BY · PubMed Central
4 Workflow of the enzyme-linked fixed-cell immunoassay.
4 Workflow of the enzyme-linked fixed-cell immunoassay.CC BY · PubMed Central
5 (a) Molecular modeling of the inactive open conformation, and the active closed one. AXXXG is the region where the two helices contact each other. (b) Structures of the featured antidepressants. (c) Fluoxetine modeled in the crevice between the TrkB transmembrane helices. (d) Rat hippocampal neurons transfected with TrkB.GFP immediately after photobleaching (center) and 2 min later (right): A untreated, B BDNF-treated, C fluoxetine-treated, or D ketamine-treated. Created by modifying open source graphics in the featured Cell paper, https://doi.org/10.1016/j.cell.2021.01.034.
5 (a) Molecular modeling of the inactive open conformation, and the active closed one. AXXXG is the region where the two helices contact each other. (b) Structures of the featured antidepressants. (c) Fluoxetine modeled in the crevice between the TrkB transmembrane helices. (d) Rat hippocampal neurons transfected with TrkB.GFP immediately after photobleaching (center) and 2 min later (right): A untreated, B BDNF-treated, C fluoxetine-treated, or D ketamine-treated. Created by modifying open source graphics in the featured Cell paper, https://doi.org/10.1016/j.cell.2021.01.034.CC BY · PubMed Central
6 Structural similarities between cholesterol and putative TrkB agonists.
6 Structural similarities between cholesterol and putative TrkB agonists.CC BY · PubMed Central
7 Structural similarities between psychedelics and antidepressants that bind the TrkB transmembrane domain and putative TrkB agonists.
7 Structural similarities between psychedelics and antidepressants that bind the TrkB transmembrane domain and putative TrkB agonists.CC BY · PubMed Central
8 Lessons from studies on small-molecule Trk modulator candidates.
8 Lessons from studies on small-molecule Trk modulator candidates.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 162 references

Research works printed but not linked: 4

  1. Frade, 1998, Nerve growth factor: two receptors, multiple functions, BioEssays, 20, 137, 10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q · doi:10.1002/(sici)1521-1878(199802)20:2<137::aid-bies6>3.0.co;2-q
  2. Ibáñez, 1994, Structure–function relationships in the neurotrophin family, J. NeuroBiol., 25, 1349, 10.1002/neu.480251104 · DOI
  3. von Zastrow, 2024, Drug Receptors & Pharmacodynamics
  4. Pattarawarapan, 2003, Molecular Basis of Neurotrophin–Receptor Interactions, J. Med. Chem., 46, 5277, 10.1021/jm030221q · DOI

Cited by

See all 13

Metadata

Authors
Thompson, T. S., Sefiani, A., & Burgess, K.
Affiliations
  • Texas A&M University (US)
  • Texas A&M Health Science Center (US)
Corresponding author
Burgess, Kevin
Venue
Journal of Medicinal Chemistry
Published
2025-07-18
Volume
68
Issue
15
Pages
15233-15259
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4412491351
Cited by
13
References
162
Citations by year
2026: 11 · 2025: 2
FWCI
1.57
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institute of Neurological Disorders and Stroke (1R21NS13834-01A1, R21NS130471)
  • Welch Foundation (AU-2182-20240404)
  • National Eye Institute (R01EY029645)
  • Texas A and M University (246292-00000)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
small molecule modulators, Trk receptors, high-throughput screening, blood-brain barrier permeability, neurodegeneration, stroke
MeSH terms
Animals, Blood-Brain Barrier, Humans, Receptor, trkA, Small Molecule Libraries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Small-Molecule Trk Agonists: Where Do We Go from Here? https://app.cochat.ai/papers/10.1021/acs.jmedchem.4c02365
The paper
Thompson, T. S., Sefiani, A., & Burgess, K. (2025). Small-Molecule Trk Agonists: Where Do We Go from Here? Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02365

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.